Discussion: DMARDs and biologic therapies in the management of inflammatory joint diseases

Austin Vaz, Jeffrey R Lisse, Warren Rizzo, Salvatore Albani

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Therapy for inflammatory joint diseases, such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, includes various conventional disease-modifying antirheumatic drugs (DMARDs). These therapeutic agents are termed DMARDs because they have the potential to reduce or prevent joint damage and preserve joint integrity and function. Conventional DMARDs are used as monotherapy or in combination and include methotrexate, leflunomide, azathioprine, ciclosporin, hydroxychloroquine, sulfasalazine, gold and minocycline. Biologic response modifiers, which are based on proteins made by living cells, are newer agents available for the treatment of various inflammatory joint diseases. Biologic therapies now approved for use in inflammatory joint diseases are TNF inhibitors, T-cell modulators and B-cell depleters. They have all been shown to have clinical efficacy and are able to retard structural damage. However, all current immune-modulating therapies also have potential side effects, and the decision to use a particular agent for treatment should be based on a thorough discussion of the benefits and risks with the patient. Newer biologic response modifiers and other immunologic therapies are currently being developed for the treatment of inflammatory joint diseases and are discussed in this review.

Original languageEnglish (US)
Pages (from-to)291-299
Number of pages9
JournalExpert Review of Clinical Immunology
Volume5
Issue number3
DOIs
StatePublished - 2009

Fingerprint

Biological Therapy
Antirheumatic Agents
Joint Diseases
Drug Therapy
leflunomide
Therapeutics
Joints
Hydroxychloroquine
Sulfasalazine
Minocycline
Psoriatic Arthritis
Ankylosing Spondylitis
Azathioprine
Methotrexate
Gold
Cyclosporine
Rheumatoid Arthritis
B-Lymphocytes
T-Lymphocytes

Keywords

  • Biologic response modifier
  • Disease-modifying antirheumatic drug
  • Methotrexate
  • Rheumatoid arthritis
  • TNF inhibitor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Discussion : DMARDs and biologic therapies in the management of inflammatory joint diseases. / Vaz, Austin; Lisse, Jeffrey R; Rizzo, Warren; Albani, Salvatore.

In: Expert Review of Clinical Immunology, Vol. 5, No. 3, 2009, p. 291-299.

Research output: Contribution to journalArticle

@article{b5b939a2b8fb48bb9d8fed3020ac8f4b,
title = "Discussion: DMARDs and biologic therapies in the management of inflammatory joint diseases",
abstract = "Therapy for inflammatory joint diseases, such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, includes various conventional disease-modifying antirheumatic drugs (DMARDs). These therapeutic agents are termed DMARDs because they have the potential to reduce or prevent joint damage and preserve joint integrity and function. Conventional DMARDs are used as monotherapy or in combination and include methotrexate, leflunomide, azathioprine, ciclosporin, hydroxychloroquine, sulfasalazine, gold and minocycline. Biologic response modifiers, which are based on proteins made by living cells, are newer agents available for the treatment of various inflammatory joint diseases. Biologic therapies now approved for use in inflammatory joint diseases are TNF inhibitors, T-cell modulators and B-cell depleters. They have all been shown to have clinical efficacy and are able to retard structural damage. However, all current immune-modulating therapies also have potential side effects, and the decision to use a particular agent for treatment should be based on a thorough discussion of the benefits and risks with the patient. Newer biologic response modifiers and other immunologic therapies are currently being developed for the treatment of inflammatory joint diseases and are discussed in this review.",
keywords = "Biologic response modifier, Disease-modifying antirheumatic drug, Methotrexate, Rheumatoid arthritis, TNF inhibitor",
author = "Austin Vaz and Lisse, {Jeffrey R} and Warren Rizzo and Salvatore Albani",
year = "2009",
doi = "10.1586/eci.09.14",
language = "English (US)",
volume = "5",
pages = "291--299",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Discussion

T2 - DMARDs and biologic therapies in the management of inflammatory joint diseases

AU - Vaz, Austin

AU - Lisse, Jeffrey R

AU - Rizzo, Warren

AU - Albani, Salvatore

PY - 2009

Y1 - 2009

N2 - Therapy for inflammatory joint diseases, such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, includes various conventional disease-modifying antirheumatic drugs (DMARDs). These therapeutic agents are termed DMARDs because they have the potential to reduce or prevent joint damage and preserve joint integrity and function. Conventional DMARDs are used as monotherapy or in combination and include methotrexate, leflunomide, azathioprine, ciclosporin, hydroxychloroquine, sulfasalazine, gold and minocycline. Biologic response modifiers, which are based on proteins made by living cells, are newer agents available for the treatment of various inflammatory joint diseases. Biologic therapies now approved for use in inflammatory joint diseases are TNF inhibitors, T-cell modulators and B-cell depleters. They have all been shown to have clinical efficacy and are able to retard structural damage. However, all current immune-modulating therapies also have potential side effects, and the decision to use a particular agent for treatment should be based on a thorough discussion of the benefits and risks with the patient. Newer biologic response modifiers and other immunologic therapies are currently being developed for the treatment of inflammatory joint diseases and are discussed in this review.

AB - Therapy for inflammatory joint diseases, such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, includes various conventional disease-modifying antirheumatic drugs (DMARDs). These therapeutic agents are termed DMARDs because they have the potential to reduce or prevent joint damage and preserve joint integrity and function. Conventional DMARDs are used as monotherapy or in combination and include methotrexate, leflunomide, azathioprine, ciclosporin, hydroxychloroquine, sulfasalazine, gold and minocycline. Biologic response modifiers, which are based on proteins made by living cells, are newer agents available for the treatment of various inflammatory joint diseases. Biologic therapies now approved for use in inflammatory joint diseases are TNF inhibitors, T-cell modulators and B-cell depleters. They have all been shown to have clinical efficacy and are able to retard structural damage. However, all current immune-modulating therapies also have potential side effects, and the decision to use a particular agent for treatment should be based on a thorough discussion of the benefits and risks with the patient. Newer biologic response modifiers and other immunologic therapies are currently being developed for the treatment of inflammatory joint diseases and are discussed in this review.

KW - Biologic response modifier

KW - Disease-modifying antirheumatic drug

KW - Methotrexate

KW - Rheumatoid arthritis

KW - TNF inhibitor

UR - http://www.scopus.com/inward/record.url?scp=77649107244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649107244&partnerID=8YFLogxK

U2 - 10.1586/eci.09.14

DO - 10.1586/eci.09.14

M3 - Article

C2 - 20477007

AN - SCOPUS:77649107244

VL - 5

SP - 291

EP - 299

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 3

ER -